Autolus Therapeutics to Report Third Quarter 2024 Financial Results and Host Conference Call on November 12, 2024

10/28/24 5:00:00 PM ET

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Get the next $AUTL alert in real time by email

LONDON, Oct. 28, 2024 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (NASDAQ:AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that it will release its third quarter 2024 financial results and operational highlights before open of US markets on Tuesday, November 12, 2024.

Management will host a conference call and webcast at 8:30 am EDT/1:30 pm BST to discuss the company's financial results and provide a general business update. Conference call participants should pre-register using this link to receive the dial-in numbers and a personal PIN, which are required to access the conference call.

A simultaneous audio webcast and replay will be accessible on the events section of Autolus' website.

Contact:

Olivia Manser

+44 (0) 7780 471568

[email protected]

Julia Wilson

+44 (0) 7818 430877

[email protected]

Susan A. Noonan

S.A. Noonan Communications

+1-917-513-5303

[email protected]

Get the next $AUTL alert in real time by email

Date	Price Target	Rating	Analyst
11/18/2024	$7.00 → $7.60	Neutral → Buy	Goldman
11/15/2024	$13.00	Neutral → Buy	Redburn Atlantic
11/9/2023	$10.00	Buy	Deutsche Bank
3/27/2023	$8.00	Overweight	Wells Fargo
3/17/2023	$5.00	Buy	Bryan Garnier

Autolus Therapeutics to Report Third Quarter 2024 Financial Results and Host Conference Call on November 12, 2024

Chat with this insight

Recent Analyst Ratings for
$AUTL

$AUTL
SEC Filings

SEC Form S-8 filed by Autolus Therapeutics plc

SEC Form 10-Q filed by Autolus Therapeutics plc

Autolus Therapeutics plc filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

$AUTL
Press Releases

Fastest customizable press release news feed in the world

Autolus Therapeutics Reports Third Quarter 2024 Financial Results and Business Updates

Autolus Therapeutics Announces FDA Approval of AUCATZYL® (obecabtagene autoleucel – obe-cel) for adults with relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL)

Autolus Therapeutics to Present Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2024 in One Oral Presentation and Three Poster Presentations

$AUTL
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

$AUTL
Large Ownership Changes

This live feed shows all institutional transactions in real time.

Autolus Therapeutics upgraded by Goldman with a new price target

Autolus Therapeutics upgraded by Redburn Atlantic with a new price target

Deutsche Bank initiated coverage on Autolus Therapeutics with a new price target

Amendment: SEC Form SC 13G/A filed by Autolus Therapeutics plc

Amendment: SEC Form SC 13G/A filed by Autolus Therapeutics plc

Amendment: SEC Form SC 13G/A filed by Autolus Therapeutics plc

$AUTL
Leadership Updates

Live Leadership Updates

Autolus Therapeutics announces appointment of Matthias Will, M.D. as Chief Development Officer

Autolus Therapeutics Announces Changes to its Board of Directors

Autolus Therapeutics announces the appointment of Robert W. Azelby to its Board of Directors

$AUTL
Financials

Live finance-specific insights

Autolus Therapeutics Reports Third Quarter 2024 Financial Results and Business Updates

Autolus Therapeutics Announces FDA Approval of AUCATZYL® (obecabtagene autoleucel – obe-cel) for adults with relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL)